Rhodiola

• Stress-related fatigue and burnout-type tiredness
• Mental stamina and concentration under acute stress or sleep loss
• Mild-to-moderate depression (preliminary, one main RCT)
• General anxiety symptoms (weak, largely uncontrolled data)
• Perceived exertion and endurance during exercise (mixed)

Rhodiola rosea is a high-altitude flowering plant native to Arctic and alpine regions of Europe, Asia, and North America, particularly the Altai Mountains of Siberia, the Carpathians, Scandinavian highlands, and the Himalayas. Traditional use spans Russian/Scandinavian folk medicine (where it has been called "golden root" and used for stress, fatigue, and altitude adaptation for centuries), Tibetan medicine (where it appears in classical formulas for high-altitude conditions), and Soviet-era military and scientific research that built the modern adaptogen evidence base. The "adaptogen" concept itself was formalized by Soviet pharmacologist Nikolay Lazarev in 1947 to describe substances that produce non-specific increases in resistance to physical, chemical, and biological stressors, a category that included Rhodiola alongside Eleutherococcus, Schisandra, and several Panax species. Israel Brekhman's subsequent Soviet research program through the 1960s-80s established the substantial Russian clinical inheritance that grounds modern Western interest. The active compound profile is distinctive among adaptogens. Rosavins (rosavin, rosin, rosarin, collectively the "rosavins") are unique to Rhodiola rosea among the genus and serve as the species-identification marker. Salidroside (also called rhodioloside) is the most pharmacologically characterized active compound, with the strongest mechanistic evidence base. Standardized commercial extracts typically target 3% rosavins and 1% salidroside (a 3:1 ratio matching natural plant proportions), the basis of the SHR-5 standardized extract used in most modern Western clinical trials. The mechanism centers on multiple neurotransmitter and hormonal systems: modulation of serotonin and dopamine availability (monoamine oxidase inhibition by salidroside is one proposed mechanism, though clinical MAO-inhibition is modest); HPA axis modulation reducing cortisol response to acute stressors; AMP-activated protein kinase (AMPK) activation supporting cellular energy metabolism; and HIF (hypoxia-inducible factor) pathway interactions relevant to the altitude adaptation traditional use. The dual pharmacology, acute stimulation-like effects within hours plus chronic adaptation effects over weeks, distinguishes Rhodiola from caffeine (acute only) and from most ashwagandha protocols (chronic only). The Olsson 2009 and Darbinyan 2007 trials established the modern Western evidence base for mental and physical fatigue in stress contexts.

Standard modern dosing of Rhodiola for stress and fatigue follows the SHR-5 clinical trial protocols: 200-680mg of standardized extract daily (3% rosavins, 1% salidroside), typically taken once or twice daily in the morning and early afternoon. The Darbinyan 2007 stress-fatigue trial used 576mg daily; Olsson 2009 chronic fatigue used the same. The Mao 2015 depression trial used 340-680mg daily. For acute cognitive and physical performance enhancement, 200-400mg taken 30-60 minutes before the task produces same-day effects. For chronic stress adaptation, daily use over 28+ days is needed to establish full adaptogenic effects. Take in the morning or early afternoon, Rhodiola has mild stimulant effects that can disrupt sleep if taken later in the day. Take with or without food; absorption is acceptable either way. Cycling protocols (3-4 weeks on, 1 week off, or similar) are common in traditional and functional medicine practice; clinical evidence for cycling necessity is limited but cycling does not appear harmful. Quality matters substantially given the species-translation concern (R. rosea vs. R. crenulata and other species without rosavin content). Verify rosavin standardization (3%) and salidroside standardization (1%) on labels. Generic 3:1 rosavin-to-salidroside extracts match the SHR-5 ratio; higher salidroside-to-rosavin ratios (some Korean products) may be from substituted species. Upper safe daily intake is not formally established; most clinical trials use doses up to 680mg/day without safety concerns.

Chronic stress/fatigue (clinical trials)

400-680mg SHR-5 daily for 28+ days

Acute cognitive/physical performance

200-400mg 30-60 minutes before task

Mild depression (Mao protocol)

340-680mg/day

Generalized anxiety (Cropley protocol)

200-400mg/day

Standardization target

3% rosavins, 1% salidroside (3:1 ratio)

Timing

Morning and early afternoon (avoid evening)

Cycling

3-4 weeks on, 1 week off (traditional; clinical evidence limited)

Time to effect

Acute: hours; Chronic adaptation: 2-4 weeks

• SHR-5 Standardized Extract (Swedish Herbal Institute)

  Rating: gold

  The standardized extract used in essentially every major modern Western Rhodiola clinical trial, Spasov 2000, Darbinyan 2007, Olsson 2009, Mao 2015, and others. Standardized to 3% rosavins and 1% salidroside (matching natural plant ratios). Substantial clinical trial inheritance; premium pricing but generally justified by quality verification. Available through licensed retail brands.

• WS 1375 Standardized Extract

  Rating: gold

  Alternative branded standardized extract used in Edwards 2012 and Cropley 2015 European trials. Comparable standardization principles to SHR-5; similar clinical evidence base. Reasonable alternative branded form with quality verification.

• Generic R. rosea Extract (3% Rosavins / 1% Salidroside)

  Rating: good

  Generic standardized extracts matching the clinical-trial standardization parameters (3% rosavins, 1% salidroside). Quality varies across manufacturers but pharmacological principles transfer. Cost-effective alternative to branded forms for users prioritizing affordability.

• Rhodiola Tincture / Liquid Extract

  Rating: good

  Traditional preparation form, particularly in Russian and Scandinavian herbal tradition. Alcoholic tinctures (typically 1:5 ratio) provide flexible dosing and rapid absorption. Quality and standardization vary substantially across products; verify rosavin/salidroside content if pursuing therapeutic use.

• Rhodiola Raw Root Powder

  Rating: caution

  Whole root powder traditional in Russian/Tibetan use. Active compound content varies enormously across sources, harvest seasons, and processing. Generally less reliable than standardized extracts for therapeutic effects. Cultural and traditional preparation contexts retain value.

• Rhodiola in Multi-Herb Adaptogen Blends

  Rating: caution

  Rhodiola appears in numerous "stress" and "energy" botanical formulations alongside ashwagandha, ginseng, eleuthero, and other adaptogens. Dose disclosure varies; therapeutic Rhodiola dose (200-600mg standardized extract) often not achieved in blended products. Verify individual Rhodiola content.

• Rhodiola + Caffeine Combinations

  Rating: good

  Common combination in modern stress/energy products. Mechanistically reasonable, caffeine for acute alertness, Rhodiola for chronic adaptation. Both compounds have established safety; combination is well-tolerated in most users. Sleep timing important as both can affect sleep onset.

• Korean and Asian Rhodiola Species Substitutes

  Rating: caution

  Substantial market substitution concern, Rhodiola crenulata, R. quadrifida, R. sachalinensis, and other species are sometimes sold as "Rhodiola" without rosavin content (rosavins are essentially unique to R. rosea). The species-translation issue (M-04 methodology flag) is real and clinically important. Verify R. rosea specification with rosavin standardization.

• Stress-related fatigue (work or life stress)

  Strength of evidence for this group: modest

  The strongest modern indication. Darbinyan 2007, Olsson 2009, Edwards 2012 support 400-600mg/day standardized extract for 28+ days. Effect sizes modest but clinically meaningful for users seeking botanical stress support. Particularly useful in burnout, chronic work stress, and life transition contexts.

• Mental fatigue and cognitive performance

  Strength of evidence for this group: modest

  Spasov 2000 student exam-stress trial and subsequent work support cognitive performance benefits in fatigue contexts. Effect sizes modest; acute pre-task dosing (200-400mg 30-60 minutes before mental work) can produce same-day effects. Reasonable component of cognitive nutrition protocols.

• Mild-to-moderate depression

  Strength of evidence for this group: modest

  Mao 2015 head-to-head trial versus sertraline showed numerically smaller antidepressant effect but substantially better tolerability. Reasonable option for users preferring botanical approach to mild depression or unable to tolerate SSRIs. Not substitute for established psychiatric care in moderate-to-severe depression.

• Athletic performance (endurance and recovery)

  Strength of evidence for this group: cautious

  De Bock 2004 and modest subsequent trials support acute endurance time-to-exhaustion improvements. Effect sizes smaller than caffeine or beta-alanine; reasonable adjunct to comprehensive sport nutrition. Soviet research tradition substantial but methodologically variable.

• Altitude adaptation (traditional use)

  Strength of evidence for this group: cautious

  Tibetan and Russian traditional use for high-altitude adaptation. HIF (hypoxia-inducible factor) pathway interactions provide mechanistic plausibility. Modern clinical evidence for altitude sickness prevention is limited but traditional inheritance is substantial. Reasonable experimental use; established altitude medications (acetazolamide) remain first-line.

• Generalized anxiety (mild)

  Strength of evidence for this group: cautious

  Cropley 2015 supports modest anxiety reduction at 400mg/day WS 1375 over 14 days. Effect sizes smaller than established anxiolytics; reasonable for users preferring botanical approach in mild anxiety. Not substitute for established treatment in clinically significant anxiety disorders.

• Bipolar disorder

  Strength of evidence for this group: cautious

  Mild stimulant effects and dopaminergic activity warrant caution in bipolar disorder. Case reports of Rhodiola-precipitated mania exist. Avoid or coordinate carefully with psychiatry in users with bipolar diagnosis.

• Pregnancy and lactation

  Strength of evidence for this group: cautious

  Limited systematic safety data in pregnancy and lactation. Some traditional contraindications in pregnancy across various herbal traditions. Generally avoid without specialist guidance.

• Ashwagandha

  Interaction: synergy

  Common adaptogen pairing. Mechanistically complementary, Rhodiola has mild stimulant character and acute effects; Ashwagandha is more sedating with chronic-only effects. The combination addresses both acute performance and chronic stress adaptation. Common in comprehensive stress/adaptogen protocols.

• Caffeine

  Interaction: synergy

  Mechanistically complementary acute energy/cognition support. Caffeine for CNS stimulation; Rhodiola for stress modulation and chronic adaptation. Common combination in modern stress/energy products. Sleep timing matters for both compounds.

• L-Theanine

  Interaction: synergy

  Mechanistically complementary for cognitive performance. L-theanine smooths stimulant edges; Rhodiola provides chronic stress adaptation. Common in modern nootropic protocols.

• B-Complex Vitamins

  Interaction: synergy

  Foundational nutritional support alongside adaptogenic action. B vitamins support stress response and energy metabolism; Rhodiola provides specific adaptogenic effects. Common in comprehensive stress nutrition.

• SSRIs and other antidepressants

  Interaction: caution

  Theoretical interaction with monoaminergic systems. Mao 2015 trial used Rhodiola as monotherapy versus sertraline rather than combination. Coordinate with prescribing physician if combining; theoretical serotonin elevation concerns warrant attention.

• MAO Inhibitors

  Interaction: caution

  Salidroside has modest MAO inhibition activity. Theoretical additive effect with pharmaceutical MAO inhibitors warrants caution. Coordinate with prescribing physician.

• Stimulant Medications (ADHD)

  Interaction: caution

  Theoretical additive stimulant effects. Most users tolerate combination; sleep timing matters. Coordinate with prescribing physician.

• Anticoagulants

  Interaction: caution

  Mild antiplatelet activity at higher doses. Theoretical additive bleeding risk with anticoagulant therapy. Coordinate with prescribing physician.

• Bipolar Disorder Medications

  Interaction: caution

  Mild stimulant effects and dopaminergic activity may destabilize mood in bipolar disorder. Case reports of Rhodiola-precipitated mania exist. Specialist psychiatric coordination essential.

Look for: explicit "Rhodiola rosea" species specification (NOT just "Rhodiola"); rosavin standardization (3% target); salidroside standardization (1% target); SHR-5 or WS 1375 branded extract identifier if seeking clinical-trial form; NSF or USP third-party verification for clinical-grade use; reasonable price (premium for branded extracts justified by trial inheritance; very high pricing without specific quality differentiation suspect). Avoid: products labeled simply "Rhodiola" without species specification; products with unspecified standardization (no rosavin or salidroside content disclosure); products with substantially elevated salidroside content (>2%) without proportional rosavins (suggests species substitution); proprietary "adaptogen" or "stress" blends obscuring Rhodiola dose; products from manufacturers without third-party testing disclosure.

Rhodiola rosea's use in human medicine spans Scandinavian Viking traditions (where it was used for stress and altitude adaptation in mountain travel), Russian folk medicine (where it has been called "golden root" for centuries and used in wedding traditions for physical vitality), Tibetan classical medicine (where it appears in formulas for "wind disorders" and high-altitude conditions), and Chinese medical use (where it overlaps with related Rhodiola species). The plant's harsh-environment growth (Arctic and alpine zones above 2000m) and traditional reputation for stress adaptation made it an obvious candidate for Soviet adaptogen research. The modern scientific era began with Nikolay Lazarev's 1947 coining of the "adaptogen" concept, a pharmacological category for substances producing non-specific resistance to physical, chemical, and biological stressors. Rhodiola was one of the foundational compounds in this framework alongside Eleutherococcus senticosus (which Brekhman would later focus on extensively). The category emerged from Soviet research priorities, supporting military performance under stress, cosmonaut performance, athletic competition under Cold War-era national pride pressures, and industrial worker performance in challenging environments. Israel Brekhman's research program at the Soviet Far East Branch of the Academy of Sciences (1960s-80s) produced substantial Russian-language research on Rhodiola, Eleutherococcus, and other adaptogens. The methodological standards were variable by modern Western criteria; the body of evidence was substantial and influenced subsequent Western research. Soviet athletes, military personnel, and cosmonauts received Rhodiola and related adaptogens through this period, generating substantial practical experience with the compounds. The Western clinical era developed through the 1990s and 2000s. The SHR-5 standardized extract from the Swedish Herbal Institute became the dominant clinical-trial form, used in Spasov 2000 (Russian medical students under exam stress), Darbinyan 2007 (Swedish patients with stress-related fatigue), Olsson 2009 (chronic fatigue), Mao 2015 (mild-to-moderate depression versus sertraline), and many subsequent trials. The WS 1375 alternative branded extract from Schwabe Pharma in Germany became the secondary clinical-trial standard. The consumer market era has grown substantially through the 2010s and 2020s, particularly in functional medicine and stress/adaptogen positioning. Rhodiola has become near-ubiquitous in modern "stress," "energy," and "adaptogen" product categories alongside ashwagandha (which has largely dominated the consumer adaptogen market post-2015). The two compounds occupy distinct pharmacological positions, Rhodiola with mild stimulant character and acute effects, ashwagandha with sedating character and chronic-only effects, and are frequently combined in modern formulations. The species substitution challenge has emerged as a significant market quality concern. Rhodiola crenulata (Tibetan high-altitude species), R. quadrifida, R. sachalinensis, and other Rhodiola species are sometimes commercially sold as "Rhodiola" without rosavin content. The 2014-2016 American Botanical Council Botanical Adulterants Prevention Program identified substantial market substitution concerns. Third-party species verification has become standard for clinical-grade products. Sustainability concerns about wild-harvested R. rosea from Altai and other Eurasian ranges have driven expansion of cultivated supply, though cultivation programs require 4-7 years to produce mature roots with full active compound content.

1. Pre-1900Scandinavian, Russian, Tibetan traditional use established
2. 1947Lazarev coins "adaptogen" concept (Soviet pharmacology)
3. 1960s-80sBrekhman Soviet research program produces substantial evidence
4. 1969First Russian Rhodiola monograph (Saratikov)
5. 1985Swedish Herbal Institute develops SHR-5 standardized extract
6. 2000Spasov medical student exam stress trial (Phytomedicine)
7. 2004De Bock acute athletic performance trial
8. 2007Darbinyan stress-fatigue trial (Nord J Psychiatry)
9. 2009Olsson chronic fatigue trial (Planta Med)
10. 2010Panossian comprehensive adaptogen review
11. 2012Edwards multi-center European stress trial
12. 2014-2016ABC Botanical Adulterants Program flags substitution issues
13. 2015Mao depression trial versus sertraline (Penn)

• Whether the substantial Soviet research inheritance translates rigorously to modern Western methodology, much of the foundational evidence is in Russian-language publications with methodologically variable trial designs.
• Whether the acute (hours-scale) and chronic (weeks-scale) effects are mechanistically related or represent distinct pharmacology.
• Optimal standardization parameters, current 3% rosavins / 1% salidroside is convention but optimization research is limited.
• Whether long-term chronic use (>6 months) maintains benefits or produces tolerance development.
• Whether Rhodiola has specific applications in chronic fatigue syndrome, fibromyalgia, or related disorders beyond the modest stress-fatigue evidence.
• How best to address the species substitution market issue, third-party species verification is the current best practice but consumer awareness remains limited.
• Whether bipolar mania case reports represent rare individual susceptibility or a more systematic concern warranting category-wide caution.
• Whether cycling protocols (3-4 weeks on / 1 week off) are clinically necessary or traditional convention without specific evidence basis.

Universally available globally as dietary supplement. Legal under DSHEA in the United States and equivalent supplement regulations in most jurisdictions. Not on WADA prohibited list, used freely by Olympic and elite athletes despite the Soviet performance research heritage. Major retail brands include Now Foods, Thorne, Pure Encapsulations, Nature's Way, Gaia Herbs, Solgar, Designs for Health, and many functional medicine brands. The SHR-5 branded extract from Swedish Herbal Institute is the gold-standard clinical-trial form; WS 1375 from Schwabe Pharma is the alternative European clinical form. Generic standardized extracts are widely available at lower cost. Russian and Eastern European markets have substantial traditional commerce in raw root and tinctures alongside Western standardized products. Sustainability concern: wild-harvest R. rosea from Altai and other ranges has produced some overharvesting concerns; sustainable cultivation programs are emerging.

Status current as of July 2026. Regulatory positions change, sometimes quickly.

Species

Rhodiola rosea (the clinical species)

Common names

Golden root, Arctic root, Rose root

Native range

Arctic and alpine regions (Eurasia, North America)

Active compounds

Rosavins (rosavin, rosin, rosarin), salidroside

Standardization target

3% rosavins, 1% salidroside (3:1 ratio)

Foundational concept

Adaptogen (Lazarev 1947)

What follows is unfinished work on our side, not a finding about Rhodiola. A short entry is not a safe entry.

• Cost and market. We have not documented what it sells for or who sells it.
• Supply chain. We have not mapped where it is made.
• Who uses it. We have not documented the user groups.
• What could change. No forward-looking summary yet.
• How it compares. We have not set it against the alternatives.
• Children and teenagers. We have not checked what is known about younger people.
• Where we land. We have not taken a position on this yet.